A Phase 1 Study to Investigate FP008 in Subjects With Advanced Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

108 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-06-12

Study Completion Date

2028-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of the phase 1 study is to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics activity of FP008 in subjects with advanced solid tumors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

3D011-08 Monotherapy in Subjects With Advanced Solid Tumors

NCT05099536

Solid Tumor, Adult

WITHDRAWN PHASE1

A Phase I Study of HS-10386 in Participants With Advanced Solid Tumors

NCT05911464

Advanced Solid Tumor

RECRUITING PHASE1

A Study of HS-20122 in Patients With Advanced Solid Tumors

NCT06927570

Advanced Solid Tumors

RECRUITING PHASE1

Phase I Study of HS-20108 in Participants With Advanced Solid Tumors

NCT06936735

Advanced Solid Tumor

NOT_YET_RECRUITING PHASE1

First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors

NCT06877650

Advanced Malignant Tumors

RECRUITING PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a first-in-human (FIH), multicenter, open-label, dose escalation and dose expansion Phase 1 study of FP008 injection in subjects with advanced solid tumors. This study will evaluate the safety, tolerability, PK, PD, immunogenicity, and preliminary antitumor activity of FP008.

The study consists two parts: Part 1 (dose escalation phase) will evaluate the safety, tolerability, PK, PD, immunogenicity, and preliminary antitumor activity of FP008 treatment, and to estimate the DRDE(s) of FP008. Part 2 (Dose expansion phase) will evaluate the safety, tolerability, PK, PD, immunogenicity, and efficacy at the different DRDE(s)/schedule(s) of FP008 in subjects with selected advanced solid tumors.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Solid Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FP008 for injection

Group Type EXPERIMENTAL

FP008 for injection

Intervention Type DRUG

FP008 should be administered intravenous weekly. Six FP008 dose levels are planned to evaluated.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FP008 for injection

FP008 should be administered intravenous weekly. Six FP008 dose levels are planned to evaluated.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Signed written ICF and be able to comply with the protocol.
2. Male and female subjects ≥18 years of age.
3. Life expectancy of \>3 months.
4. Laboratory values for sufficient organ function at screening.
5. Toxicity from prior antitumor treatment has resolved to ≤Grade 1 as defined by NCI CTCAE v5.0.
6. Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to the start of FP008.
7. Male or women of childbearing potential, if sexually active, must agree to use contraception considered adequate and appropriate by the investigator during the period of study drug administration and for at least 5 months after the last dose of FP008.
8. ECOG performance status of 0 to 1.
9. Histologically or cytologically confirmed malignancy diagnosis and at least one measurable documented advanced/unresectable or metastatic solid tumor as assessed by RECIST v1.1.
10. Documented progressive disease, refractory/resistance/intolerant to standard therapy (documented the reason(s) why they are intolerant to standard therapy by the investigator), or there is no standard therapy.

Exclusion Criteria

1. Subjects who have received other IL-10 agents.
2. A history of other malignancies other than basal cell carcinoma of skin, squamous cell carcinoma of skin, non-muscle invasive bladder cancer, thyroid papillary carcinoma or carcinoma in situ of the cervix that have been cured for 2 years after effective treatment.
3. Received live vaccine within 30 days prior to the first dose of FP008.
4. Not completely recovered from the effects of major surgery or significant traumatic injury at least 14 days before the first dose of FP008.
5. Known hypersensitivity to either the drug substances or inactive ingredient of FP008.
6. Subjects with diagnosis of immunodeficiency, organ transplant requiring immunosuppressive therapy, or allogeneic bone marrow or hematopoietic stem cell transplant.
7. Daily requirement for corticosteroids within 2 weeks prior to first dose of FP008.
8. Any other medical disorder, physical exam finding, laboratory finding, altered mental status, or psychiatric condition that the investigator considers unsuitable for participation in the study.
9. Cardiovascular dysfunction or clinically significant cardiac disease.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No